Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see how well the experimental drug
camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally
radiotherapy for their disease. All patients will receive 200 mg of camrelizumab
intravenously on Day 1 of each 21-day cycle. Patients will receive the study drug for up to
18 cycles.